Physician profile
Sandra L Risoldi
NPI 1972745206
$3,137.98
in general payments reported to CMS, 2019-2025
12 companies · $842 in 2025
The $842 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $59.68 · 2023: $616 · 2024: $1,621 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,078.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $2,004.34 | 2022-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $490.02 | 2023-2025 | |
| Neuronetics, INC. | $244.49 | 2023-2024 | Neurostar Tms Therapy System |
| Lundbeck LLC | $99.72 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $97.79 | 2024 | Rexulti |
| Neurocrine Biosciences, INC. | $57.15 | 2023-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $34.44 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $33.23 | 2025 | Austedo Xr |
| Neos Therapeutics, Lp | $30.56 | 2024 | Adzenys Xr-Odt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.03 | 2025 | Caplyta |
| Almatica Pharma LLC | $15.43 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.78 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Risoldi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.